List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7391669/publications.pdf Version: 2024-02-01

		47006	29157
107	11,467	47	104
papers	citations	h-index	g-index
113	113	113	7797
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy. Digestive Diseases, 2022, 40, 322-334.	1.9	3
2	p70 Ribosomal Protein S6 Kinase Is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 95-112.	4.5	5
3	Marked Increase of Gamma-Glutamyltransferase as an Indicator of Drug-Induced Liver Injury in Patients without Conventional Diagnostic Criteria of Acute Liver Injury. Visceral Medicine, 2022, 38, 223-228.	1.3	3
4	Acute liver injury following methylprednisolone pulse therapy: 13 cases from a prospectively collected cohort. European Journal of Gastroenterology and Hepatology, 2022, 34, 457-461.	1.6	3
5	Challenges and Future of Drug-Induced Liver Injury Research—Laboratory Tests. International Journal of Molecular Sciences, 2022, 23, 6049.	4.1	10
6	Monocyte-Derived Hepatocyte-Like Cell Test: A Novel Tool for in vitro Identification of Drug-Induced Liver Injury in Patients with Herbal or Dietary Supplements. Digestion, 2021, 102, 650-653.	2.3	4
7	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. Journal of Hepatology, 2021, 74, 330-339.	3.7	76
8	Further evidence for the hepatotoxic potential of metamizole. British Journal of Clinical Pharmacology, 2021, 87, 1587-1588.	2.4	4
9	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	3.7	149
10	Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver Injury. Digestive Diseases, 2021, 39, 275-282.	1.9	12
11	Liver Injury Associated with Metamizole Exposure: Features of an Underestimated Adverse Event. Drug Safety, 2021, 44, 669-680.	3.2	16
12	SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway. International Journal of Oncology, 2021, 58, .	3.3	13
13	Ashwagandha-Induced Liver Injury: Self-Reports on Commercial Websites as Useful Adjunct Tools for Causality Assessment. American Journal of Gastroenterology, 2021, 116, 2151-2152.	0.4	9
14	Novel predictors for liver transplantation or death in drug-induced acute liver failure. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	1.6	1
15	PO41â€Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , .		1
16	Albumin Might Attenuate Bacteria-Induced Damage on Kupffer Cells for Patients with Chronic Liver Disease. Cells, 2021, 10, 2298.	4.1	3
17	Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study. European Journal of Gastroenterology and Hepatology, 2021, 33, 1185-1193.	1.6	10
18	To Protect Fatty Livers from Ischemia Reperfusion Injury: Role of Ischemic Postconditioning. Digestive Diseases and Sciences, 2021, 66, 1349-1359.	2.3	0

#	Article	IF	CITATIONS
19	Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1327-1343.	3.3	10
20	Drug-Induced Liver Injury (DILI): A Major Challenge. Drug Research, 2021, 71, S7-S7.	1.7	2
21	Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut, 2020, 69, 168-176.	12.1	67
22	Patients with cirrhosis and SBP: Increase in multidrugâ€resistant organisms and complications. European Journal of Clinical Investigation, 2020, 50, e13198.	3.4	8
23	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	3.7	223
24	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut, 2020, 69, 764-780.	12.1	112
25	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	3.7	282
26	IL-18 But Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2020, 21, 8602.	4.1	14
27	Acute liver injury in a patient with adult-onset Still's disease—the challenge of differential diagnosis. Oxford Medical Case Reports, 2020, 2020, omaa102.	0.4	1
28	Metabolic implication of tigecycline as an efficacious secondâ€line treatment for sorafenibâ€resistant hepatocellular carcinoma. FASEB Journal, 2020, 34, 11860-11882.	0.5	13
29	Drugâ€induced Liver Injury by Checkpoint Inhibitors: Benefit of a Causality Assessment Tool. Hepatology Communications, 2020, 4, 1552-1554.	4.3	0
30	Pretreatment with zinc protects Kupffer cells following administration of microbial products. Biomedicine and Pharmacotherapy, 2020, 127, 110208.	5.6	4
31	Albumin in decompensated cirrhosis: new concepts and perspectives. Gut, 2020, 69, 1127-1138.	12.1	190
32	Kupffer cell activation by different microbial lysates: Tollâ€like receptorâ€2 plays pivotal role on thromboxane A ₂ production in mice and humans. European Journal of Immunology, 2020, 50, 1988-1997.	2.9	2
33	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. Journal of Hepatology, 2020, 73, 113-120.	3.7	58
34	Prognostic Significance and Functional Relevance of Olfactomedin 4 in Early-Stage Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 2020, 11, e00124.	2.5	6
35	Inhibition of Cyclinâ€Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy. Hepatology, 2019, 69, 376-393	7.3	38
36	Drug-Drug Combinations Can Enhance Toxicity as Shown by Monocyte-Derived Hepatocyte-like Cells From Patients With Idiosyncratic Drug-Induced LiverÂlnjury. Toxicological Sciences, 2019, 171, 296-302.	3.1	14

#	Article	IF	CITATIONS
37	Early ALT response to corticosteroid treatment distinguishes idiosyncratic drugâ€induced liver injury from autoimmune hepatitis. Liver International, 2019, 39, 1906-1917.	3.9	33
38	lschemic Postconditioning (IPostC) Protects Fibrotic and Cirrhotic Rat Livers after Warm Ischemia. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-11.	1.9	2
39	Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. Cellular Oncology (Dordrecht), 2019, 42, 705-715.	4.4	18
40	Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl4 mouse model. Laboratory Investigation, 2019, 99, 1906-1917.	3.7	19
41	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology, 2019, 157, 149-162.	1.3	178
42	Acute Liver Failure During Pirfenidone Treatment Triggered by Coâ€Medication With Esomeprazole. Hepatology, 2019, 70, 1869-1871.	7.3	10
43	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	4.8	134
44	Evaluating the best empirical antibiotic therapy in patients with acute-on-chronic liver failure and spontaneous bacterial peritonitis. Digestive and Liver Disease, 2019, 51, 1300-1307.	0.9	13
45	The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma. Cell Death Discovery, 2019, 5, 86.	4.7	41
46	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology, 2019, 156, 1368-1380.e10.	1.3	296
47	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. Journal of Hepatology, 2019, 70, 639-647.	3.7	101
48	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. Journal of Hepatology, 2019, 70, 398-411.	3.7	225
49	Orchestration of Tryptophanâ€Kynurenine Pathway, Acute Decompensation, and Acuteâ€onâ€Chronic Liver Failure in Cirrhosis. Hepatology, 2019, 69, 1686-1701.	7.3	80
50	The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma. Digestion, 2019, 100, 15-26.	2.3	5
51	The effects of hepatic steatosis on thromboxane A2 induced portal hypertension. GastroenterologÃa Y HepatologÃa, 2019, 42, 534-541.	0.5	1
52	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in PatientsÂWith Hepatorenal Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 1792-1800.e3.	4.4	127
53	Mitochondrial adaptation in steatotic mice. Mitochondrion, 2018, 40, 1-12.	3.4	54
54	Cell death markers in patients with cirrhosis and acute decompensation. Hepatology, 2018, 67, 989-1002.	7.3	76

4

#	Article	IF	CITATIONS
55	Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2018, 16, 1488-1494.e5.	4.4	45
56	Herbal tea and liver injury – Tea extract or comedication can make a difference. Journal of Hepatology, 2018, 69, 547-548.	3.7	7
57	Proteomics Analysis of Monocyte-Derived Hepatocyte-Like Cells Identifies Integrin Beta 3 as a Specific Biomarker for Drug-Induced Liver Injury by Diclofenac. Frontiers in Pharmacology, 2018, 9, 699.	3.5	23
58	Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol. Hepatology International, 2017, 11, 141-142.	4.2	0
59	Plasma cystatin C is a predictor of renal dysfunction, acuteâ€onâ€chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology, 2017, 66, 1232-1241.	7.3	72
60	Tapering of Immunosuppression and Sustained Treatment With Nivolumab in a Liver Transplant Recipient. Gastroenterology, 2017, 152, 1631-1633.	1.3	59
61	Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut, 2017, 66, 1154-1164.	12.1	370
62	Data on chow, liver tissue and mitochondrial fatty acid compositions as well as mitochondrial proteome changes after feeding mice a western diet for 6–24 weeks. Data in Brief, 2017, 15, 163-169.	1.0	9
63	Systemic inflammation in decompensated cirrhosis: Characterization and role in acuteâ€onâ€chronic liver failure. Hepatology, 2016, 64, 1249-1264.	7.3	550
64	Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury. Gut, 2016, 65, 1555-1563.	12.1	48
65	Rescue management of early complications after liver transplantation—key for the long-term success. Langenbeck's Archives of Surgery, 2016, 401, 389-396.	1.9	5
66	Reliable Quantification of the Potential for Equations Based on Spot Urine Samples to Estimate Population Salt Intake: Protocol for a Systematic Review and Meta-Analysis. JMIR Research Protocols, 2016, 5, e190.	1.0	4
67	Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4 ^{-/-} mouse model. World Journal of Hepatology, 2016, 8, 401.	2.0	40
68	Clinical Course of acuteâ€onâ€chronic liver failure syndrome and effects on prognosis. Hepatology, 2015, 62, 243-252.	7.3	493
69	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut, 2015, 64, 531-537.	12.1	405
70	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. Journal of Hepatology, 2015, 62, 831-840.	3.7	289
71	Targeting cyclin dependent kinase 5 in hepatocellular carcinoma – A novel therapeutic approach. Journal of Hepatology, 2015, 63, 102-113.	3.7	72
72	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. Journal of Hepatology, 2014, 61, 1038-1047.	3.7	741

#	Article	IF	CITATIONS
73	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013, 144, 1426-1437.e9.	1.3	2,211
74	Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut, 2012, 61, 108-116.	12.1	121
75	Human monocyte-derived cells with individual hepatocyte characteristics: a novel tool for personalized in vitro studies. Laboratory Investigation, 2012, 92, 926-936.	3.7	29
76	TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut, 2010, 59, 988-1000.	12.1	208
77	Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgraduate Medical Journal, 2008, 84, 662-670.	1.8	504
78	The patient with refractory ascites. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 551-560.	2.4	16
79	Liver injury and liver protection: mechanisms and novel treatment strategies. Liver International, 2006, 26, 902-903.	3.9	5
80	Progress in treatment of massive ascites and hepatorenal syndrome. World Journal of Gastroenterology, 2006, 12, 516.	3.3	11
81	Benefit of TIPS for patients with refractory or recidivant ascites: Serum bilirubin may make the difference. Hepatology, 2005, 41, 217-217.	7.3	23
82	Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcohol-induced cirrhosis. Transplant International, 2003, 16, 639-641.	1.6	23
83	Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gastroenterology, 2003, 124, 933-939.	1.3	280
84	Improved Quality of Life in Patients with Refractory or Recidivant Ascites after Insertion of Transjugular Intrahepatic Portosystemic Shunts. Digestion, 2002, 66, 127-130.	2.3	52
85	In-vivo quantification of hepatic 11β-hydroxysteroid dehydrogenase type I activity–a preliminary study. Clinical Biochemistry, 2002, 35, 655-657.	1.9	6
86	Short-term treatment with mycophenolic acid increases bile flow in continuously perfused and cold-preserved rat livers and does not affect hepatic ischemia-reperfusion injury. Transplant International, 2002, 15, 265-271.	1.6	2
87	Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology, 2002, 35, 630-634.	7.3	122
88	Determination of plasma adrenomedullin concentrations with commercial radioimmunoassay kits: A note of caution. Liver Transplantation, 2000, 6, 384-386.	2.4	4
89	A Comparison of Paracentesis and Transjugular Intrahepatic Portosystemic Shunting in Patients with Ascites. New England Journal of Medicine, 2000, 342, 1701-1707.	27.0	531
90	Prevention of Kupffer cell-induced oxidant injury in rat liver by atrial natriuretic peptide. American Journal of Physiology - Renal Physiology, 1999, 276, G1137-G1144.	3.4	53

#	Article	IF	CITATIONS
91	Hepatic blood flow and splanchnic oxygen consumption in patients with liver failure. Effect of high-volume plasmapheresis. Hepatology, 1999, 29, 347-355.	7.3	68
92	Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology, 1999, 30, 870-875.	7.3	177
93	Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: Comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology, 1998, 28, 683-688.	7.3	73
94	The guanylate cyclase-coupled natriuretic peptide receptor: A new target for prevention of cold ischemia-reperfusion damage of the rat liver. Hepatology, 1998, 28, 1309-1317.	7.3	64
95	Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: Role of splanchnic and renal passage and liver function. Hepatology, 1995, 21, 735-739.	7.3	101
96	Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. Journal of Hepatology, 1993, 17, 353-358.	3.7	43
97	Medical treatment of ascites in cirrhosis. Journal of Hepatology, 1993, 17, S4-S9.	3.7	24
98	Pathophysiology of elevated ascites fluid cholesterol in malignant ascites. Journal of Hepatology, 1992, 14, 244-248.	3.7	25
99	Role of the liver in splanchnic extraction of atrial natriuretic factor in the rat. Hepatology, 1992, 16, 790-793.	7.3	11
100	Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, β-adrenergic blockade and atrial natriuretic factor. Hepatology, 1992, 16, 1163-1170.	7.3	76
101	Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, β-adrenergic blockade and atrial natriuretic factor. Hepatology, 1992, 16, 1163-1170.	7.3	3
102	Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Gastroenterology, 1991, 101, 1060-1067.	1.3	157
103	Altered density of glomerular binding sites for atrial natriuretic factor in bile duct–ligated rats with ascites. Hepatology, 1991, 13, 562-566.	7.3	23
104	Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence. Cancer, 1991, 68, 1808-1814.	4.1	61
105	Ascitic fluid concentrations of fibronectin and cholesterol: comparison of differential diagnostic value with the conventional protein determination. Liver, 1990, 10, 152-157.	0.1	15
106	Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. Hepatology, 1989, 9, 417-422.	7.3	74
107	Value of ascitic lipids in the differentiation between cirrhotic and malignant ascites. Hepatology, 1986, 6, 239-243.	7.3	69